Updates on Efficacy/Safety Results from MonumenTAL-1 (Talquetamab) Presented at ASCO 2022
Dr. Monique C. Minnema Provides Updates on Efficacy/Safety Results from MonumenTAL-1 (Talquetamab) in RRMM patients
Abstract Title:
Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.
What is the purpose of this trial?
The purpose of this study is to characterize the safety of talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for talquetamab (Part 1 [Dose Escalation]) and to further characterize the safety of talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 [Dose Expansion]).
Talquetamab is a first-in-class, bispecific IgG4 antibody that binds to both GPRC5D and CD3 receptors, mediating T-cell–activated lysis of GPRC5D+ MM cells. G protein-coupled receptor family C group 5 member D (GPRC5D), which has limited expression in normal human tissue but is highly expressed on malignant plasma cells, is a promising target for multiple myeloma (MM) immunotherapy.
The primary objectives were to identify the recommended phase 2 doses (RP2Ds) (part 1) and assess talquetamab’s safety and tolerability at the RP2Ds (part 2).
Here we report updated results with additional patients (pts) and longer follow-up from MonumenTAL-1, a phase 1 trial of talquetamab in relapsed/refractory multiple myeloma (RRMM).
In this video:
Dr. Monique C. Minnema (University Medical Center Utrecht—Utrecht, Netherlands) provides updates on efficacy/safety results from MonumenTAL-1 (talquetamab) in relapsed/refractory multiple myeloma (RRMM) patients.
Conclusion:
These data show that both recommended phase 2 doses (RP2Ds) of talquetamab have comparable safety, efficacy, and pharmacokinetic profiles and confirm talquetamab as a novel, first-in-class therapy with highly promising efficacy in a heavily pretreated RRMM patient population.
Clinical trial information: NCT03399799
Doctor Bio:
Monique Minnema, MD, PhD is a hematologist at the Department of Hematology in University Medical Center (UMC) Utrecht in Utrecht, Netherlands. She specializes in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasias, like multiple myeloma, AL amyloidosis, and Waldenström’s Macroglobulinemia. She is the medical head of the hematology research team and the biobank LML. She is a member of the HOVON working parties for multiple myeloma, lymphoma, and vice-chair of the Lunenburg Lymphoma consortium (LLPC) for phase I/II studies. Dr. Minnema is the principal investigator of the HOVON 104 trial for patients with AL amyloidosis, the clinical studies with the monoclonal antibody daratumumab in multiple myeloma and AL amyloidosis and CAR T-cell treatment in relapsed Non-Hodgkin's Lymphoma. Prof. Dr. Minnema is the chair for the national guidelines for treatment of AL amyloidosis and diagnostics in plasma cell dyscrasias.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
